Şunu aradınız:: serotonergic (İngilizce - Maltaca)

serotonergic agents
sustanzi serotonerġiċi

potential serotonergic interactions
interazzjonijiet serotonerġiċi potenzjali

serotonergic drugs (e.g.
mediċini serotonerġiċi (eż.

serotonergic medicinal products (e.g.
prodotti mediċinali serotoninerġiċi (eż.

antidepressants with serotonergic effect can lower the seizure threshold.
antidepressanti b’effett serotonerġiku jistgħu jbaxxu l-limitu tal-aċċessjonijiet.

taking medicines with a so-called serotonergic effect, such as:
qed tieħu mediċini b’effett li jissejjaħ serotonerġiku, bħal:

these symptoms may be due to either serotonergic effects or exposure symptoms.
dawn is - sintomi jistgħu jkunu kkawżati jew minħabba effetti serotonerġiċi jew minħabba effetti minħabba l - espożizzjoni.

are taking medicines with a so-called serotonergic effect, such as:
qed tieħu mediċini b’effett li jissejjaħ serotonerġiku, bħal:

these symptoms could be due to either discontinuation effects or excess serotonergic activity.
dawn is-sintomi jistgħu jkunu kkawżati mill-effetti ta’ twaqqif jew minn attività serotonerġika eċċessiva.

paliperidone binds strongly to serotonergic 5-ht2- and dopaminergic d2-receptors.
paliperidone jintrabat b’mod qawwi mar-riċetturi serotonerġiċi 5-ht2 u dopaminerġiċi d2.

as with other serotonergic medicinal products, discontinuation symptoms may occur in the neonate after maternal duloxetine use near term.
bħal bl-użu ta’ mediċini serotonerġiċi oħra, sintomi ta’ sospensjoni jistgħu jseħħu f’trabi tat-twelid wara l-użu fl-omm ta’ duloxetine qrib il-ħlas.

lurasidone and its active metabolite id-14283 both contribute to the pharmacodynamic effect at the dopaminergic and serotonergic receptors.
lurasidone u l-metabolit attiv tiegħu id-14283 it-tnejn jikkontribwixxu għall-effett farmakodinamiku fir-riċetturi dopaminerġiċi u serotonerġiċi.

in rare cases, serotonin syndrome has been reported in patients using ssris/snris concomitantly with serotonergic agents.
f’każi rari, ġie rrappurtat sindromu ta’ serotonin f’pazjenti li jużaw ssris/snris fl-istess ħin ma’ sustanzi serotoninerġiċi.

as a result of inhibiting serotonin uptake, fluoxetine enhances serotonergic neurotransmission and produces functional effects resulting from increased activation of serotonin receptors.
bħala riżultat tal-inibizzjoni tat-teħid ta’ serotonin, fluoxetine jintensifika n-newrotrassmissjoni serotonerġika u jipproduċi effetti funzjonali li jirriżultaw mill-attivazzjoni ogħla ta’ riċettur ta’ serotonin.

animal studies indicate that noradrenergic and serotonergic neurons are coupled (i.e. limit the activity of each other)
xi trattamenti jistgħu jintużaw ukoll għal perijodu qasir biex jgħinu lil individwi jieqfu jieħdu d-drogi kollha.

dextromethorphan may increase the risk of serotonin syndrome, and this risk is increased by overdose, particularly if taken with other serotonergic agents, ssris or tricyclic antidepressants.
dextromethorphan jista’ jżid ir-riskju tas-sindromu tas-serotonin, u dan ir-riskju jiżdied b’doża eċċessiva, b’mod partikolari jekk jittieħed ma’ sustanzi serotonerġiċi oħra, ssris jew antidepressanti triċikliċi.

serotonergic effects at doses of tedizolid phosphate up to 30-fold above the human equivalent dose did not differ from vehicle control in a mouse model that predicts brain serotonergic activity.
l-effetti serotonerġiċi b’dożi ta’ tedizolid phosphate sa 30 darba aktar mid-doża ekwivalenti tal- bniedem ma kinux differenti mill-kontroll bis-sustanza li fiha tinġarr is-sutanza attiva f’mudell ta’ ġurdien li jbassar l-attività serotonerġika tal-moħħ.

there have been reports of serotonin syndrome following concomitant use of 5-ht3 antagonists and other serotonergic drugs (including ssris and snris).
kien hemm rapport tas-sindrome ta’ serotonin wara l-użu fl-istess ħin ta’ antagoisti ta’ 5-ht3 u mediċini serotonerġiċi oħrajn (li jinkludu ssris u snris).

the mechanism of action of vortioxetine is thought to be related to its direct modulation of serotonergic receptor activity and inhibition of the serotonin (5-ht) transporter.
il-mekkaniżmu ta’ azzjoni ta’ vortioxetine huwa maħsub li huwa relatat mal-modulazzjoni dirett tal- attività tar-riċettur serotonerġiku u l-inibizzjoni tat-trasportatur ta’ serotonin (5-ht).

over time, noradrenergic and serotonergic neurons become autonomous and hyper-reactive to external stimuli and arguably this druginduced long-term uncoupling explains dysfunctions in motivation and in the ability to inhibit impulses.
maż-żmien, in-newroni noradrenerġiċi u serotonerġiċi jsiru awtonomi u reattivi żżejjed għall-istimuli esterni u b’mod diskutibbli din is-separazzjoni fuq żmien twil ikkaġunata mid-drogi tista’ tispjega l-funzjonament ħażin filmotivazzjoni u fl-abilità ta’ inibizzjoni ta’ agir skond ix-xewqa tal-mument.